REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA

This study is for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It tests a combination of two drugs: epcoritamab, which helps the immune system attack cancer cells, and ibrutinib, which blocks signals that help cance…

This study tests whether adding an experimental drug called ST-067 to standard CAR T-cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 adults will receive the combination therapy to see if it i…

This early-phase trial is testing a CAR-T cell therapy (axicabtagene ciloleucel) in 20 adults with HIV who have aggressive B-cell non-Hodgkin lymphoma that came back or didn't respond to prior treatment. The therapy uses a patient's own immune cells, modified to recognize and att…

This study tests a two-step treatment for people with a fast-growing lymphoma that returned or didn't respond to initial therapy. First, patients receive a combination of tafasitamab (an antibody) and lenalidomide, followed by a standard chemotherapy regimen (ICE). The goal is to…

This study tests whether combining two targeted drugs (loncastuximab tesirine and mosunetuzumab) can shrink or control aggressive B-cell lymphomas that have returned or stopped responding to prior treatments. About 36 adults will receive the drug combination, and researchers will…

This study tests whether giving two drugs, golcadomide and rituximab, before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to keep the disease in check so more patients can qualify for…

This study tests whether giving the drug odronextamab before CAR-T cell therapy can help control aggressive large B-cell lymphomas that have returned or not responded to prior treatment. About 27 adults will receive odronextamab to slow disease progression and increase the chance…